Revolution Medicines to Unveil Daraxonrasib at ASCO
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- American Society of Clinical Oncology (ASCO) holds its annual meeting in Chicago from June 1‑2, 2026.
- Revolution Medicines will present full Phase 3 results of its RAS‑blocking pancreatic cancer drug daraxonrasib at the ASCO plenary session on Sunday afternoon.
- RASolute 302 is the Phase 3 trial whose data will be featured at the ASCO meeting.
Why it matters: Pancreatic‑cancer patients stand to gain a novel therapy if daraxonrasib’s Phase 3 data prove positive, while Revolution Medicines’ investors and the broader biotech market will feel the immediate impact of the trial’s outcome.
